UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
暂无分享,去创建一个
A. Carrato | V. Moreno | A. Abad | E. Martínez-Balibrea | A. Martínez-Cardús | M. Benavides | M. Navarro | E. Aranda | B. Massutí | J. Manzano | E. Marcuello | M. Valladares | L. Layos | A. Ginés | A. Ginés | B. Massutí | E. Aranda | Victor Moreno | Manuel Valladares | Matilde Navarro | Enrique Aranda
[1] M. Parmar,et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Soma Das,et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Federico Innocenti,et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Carrato,et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] R. Goldberg,et al. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. , 2008, The oncologist.
[6] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.
[7] E. Guinó,et al. Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. , 2008, European journal of cancer.
[8] Jin-Hwang Liu,et al. UGT1A1*28 polymorphism predicts irinotecan‐induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma , 2008, Cancer.
[9] Susan Groshen,et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer , 2008, Pharmacogenetics and genomics.
[10] Joseph G Ibrahim,et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.
[11] P. Laurent-Puig,et al. UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan , 2007, Clinical Cancer Research.
[12] Joan Valls,et al. SNPStats: a web tool for the analysis of association studies , 2006, Bioinform..
[13] E. Shin,et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Sharon Marsh,et al. Thymidylate synthase pharmacogenetics , 2005, Investigational New Drugs.
[15] M. Manns,et al. Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene , 2005, Molecular Pharmacology.
[16] N. Meropol,et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] E. Gamelin,et al. Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity , 2004, Clinical Cancer Research.
[18] M. Baiget,et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.
[19] S. Groshen,et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. , 2004, Pharmacogenetics.
[20] Soma Das,et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] L. Grochow,et al. Camptothecin analogues: studies from The Johns Hopkins Oncology Center , 2004, Cancer Chemotherapy and Pharmacology.
[22] O. Cummings,et al. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] G. Watanabe,et al. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. , 2002, Anticancer research.
[24] C. Guillemette,et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.
[25] N. Magné,et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] G. Watanabe,et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] B. Iacopetta,et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.
[28] S. Groshen,et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.
[29] C. Guillemette,et al. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. , 2000, Pharmacogenetics.
[30] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[31] M. Ciotti,et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. , 1999, Biochemical and biophysical research communications.
[32] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[33] M. Ratain,et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.
[34] B. Burchell,et al. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.
[35] H. Kuga,et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.